Yahya Ahmadipour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yahya Ahmadipour has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Ramazan Jabbarli
Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany
21 shared publications - Ulrich Sure
Department of Neurosurgery and Spine Surgery, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
20 shared publications - Marvin Darkwah Oppong
Department of Neurosurgery and Spine Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
16 shared publications - Philipp Dammann
Department of Neurosurgery and Spine Surgery, University Hospital Essen, 45122 Essen, Germany
15 shared publications - Laurèl Rauschenbach
Department of Neurosurgery and Spine Surgery, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
14 shared publications - Oliver Gembruch
Department of Neurosurgery and Spine Surgery, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
14 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 912
Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF)
Background: Tumor Treating Fields improve survival when started after chemoradiotherapy in newly diagnosed glioblastoma, but the safety and feasibility of initiating treatment before and during radiotherapy remain uncertain. Methods: PriCoTTF is a prospective, open-label, nonrandomized, multicenter phase I/II trial. Arm A enrolled adults aged 18 to 70 years with newly diagnosed IDH-wildtype glioblastoma or gliosarcoma, Karnofsky Performance Status of at least 60, and planned focal radiotherapy to 60 Gy in 30 fractions. TTFields at 200 kHz were initiated 2 to 4 weeks after surgery and 1 to 2 weeks before radiotherapy. The primary endpoint was protocol-defined treatment-limiting toxicity from TTFields initiation through 4 weeks after radiotherapy. Results: Twenty evaluable patients comprised the Arm A feasibility cohort. No protocol-defined treatment-limiting toxicities occurred (0 of 20 patients; exact 95% CI, 0.0%-16.8%). Grade 3 or higher adverse events occurred in 12 patients (60%), predominantly hematologic toxicity attributable to chemoradiotherapy; lymphopenia occurred in 6 patients (30%). Median usage through visit 4 was 76.5%, and median time to first attainment of at least 75% daily use was 2 days. Median progression-free survival was 6.9 months (95% CI, 2.7–14.0), and median overall survival was 18.0 months (95% CI, 12.1–19.9). Conclusions: Initiation of TTFields before and during radiotherapy was feasible and was not associated with protocol-defined treatment-limiting toxicity in the Arm A cohort. Because the TLT definition was narrow and efficacy analyses were exploratory and exposure-conditioned, these findings should be interpreted as feasibility data rather than evidence of improved tumor control or survival. The results support randomized evaluation of earlier TTFields integration in newly diagnosed glioblastoma. Trial registration: German Clinical Trials Register DRKS00016667, registered 26 February 2019.
- 27 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 912
Open AccessSafety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF)
Background: Tumor Treating Fields improve survival when started after chemoradiotherapy in newly diagnosed glioblastoma, but the safety and feasibility of initiating treatment before and during radiotherapy remain uncertain. Methods: PriCoTTF is a prospective, open-label, nonrandomized, multicenter phase I/II trial. Arm A enrolled adults aged 18 to 70 years with newly diagnosed IDH-wildtype glioblastoma or gliosarcoma, Karnofsky Performance Status of at least 60, and planned focal radiotherapy to 60 Gy in 30 fractions. TTFields at 200 kHz were initiated 2 to 4 weeks after surgery and 1 to 2 weeks before radiotherapy. The primary endpoint was protocol-defined treatment-limiting toxicity from TTFields initiation through 4 weeks after radiotherapy. Results: Twenty evaluable patients comprised the Arm A feasibility cohort. No protocol-defined treatment-limiting toxicities occurred (0 of 20 patients; exact 95% CI, 0.0%-16.8%). Grade 3 or higher adverse events occurred in 12 patients (60%), predominantly hematologic toxicity attributable to chemoradiotherapy; lymphopenia occurred in 6 patients (30%). Median usage through visit 4 was 76.5%, and median time to first attainment of at least 75% daily use was 2 days. Median progression-free survival was 6.9 months (95% CI, 2.7–14.0), and median overall survival was 18.0 months (95% CI, 12.1–19.9). Conclusions: Initiation of TTFields before and during radiotherapy was feasible and was not associated with protocol-defined treatment-limiting toxicity in the Arm A cohort. Because the TLT definition was narrow and efficacy analyses were exploratory and exposure-conditioned, these findings should be interpreted as feasibility data rather than evidence of improved tumor control or survival. The results support randomized evaluation of earlier TTFields integration in newly diagnosed glioblastoma. Trial registration: German Clinical Trials Register DRKS00016667, registered 26 February 2019.
- Open Access
- 28 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2277
Molecular Pathways and Circulating Biomarkers in Cerebral Cavernous Malformations—A Systematic Review
Cerebral Cavernous Malformations (CCMs) are low-flow vascular lesions located within the central nervous system, with a reported prevalence in the general population of 0.16–0.5%. Patients with CCMs may remain asymptomatic or present new onset symptoms such as seizures or focal neurological deficits often related to the occurrence of intracerebral hemorrhage. CCM may appear sporadic or as part of familial forms linked to mutations in the CCM-gene cluster, affecting endothelial cell integrity and triggering molecular cascades, including the MEKK3/KLF2/4 signaling pathway. Recent studies have highlighted the roles of inflammatory, angiogenic, and coagulation pathways alongside the emerging evidence of a gut–brain axis influencing microbiome-driven TLR4 signaling. This systematic review aims to describe molecular biomarkers associated with CCM pathophysiology, emphasizing their potential use as diagnostic and prognostic tools. Circulating plasma biomarkers such as CRP, vitamin D, and interleukins may reflect ongoing inflammatory and endothelial processes, while some imaging biomarkers like Quantitative Susceptibility Mapping (QSM) have shown a correlation with iron deposition and vascular leakage. Leveraging both circulating and imaging biomarkers may improve the therapeutic decision-making process. Further studies are encouraged to validate these findings and to facilitate the development of personalized, evidence-based strategies for the management of CCM.
- 28 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2277
Open AccessMolecular Pathways and Circulating Biomarkers in Cerebral Cavernous Malformations—A Systematic Review
Cerebral Cavernous Malformations (CCMs) are low-flow vascular lesions located within the central nervous system, with a reported prevalence in the general population of 0.16–0.5%. Patients with CCMs may remain asymptomatic or present new onset symptoms such as seizures or focal neurological deficits often related to the occurrence of intracerebral hemorrhage. CCM may appear sporadic or as part of familial forms linked to mutations in the CCM-gene cluster, affecting endothelial cell integrity and triggering molecular cascades, including the MEKK3/KLF2/4 signaling pathway. Recent studies have highlighted the roles of inflammatory, angiogenic, and coagulation pathways alongside the emerging evidence of a gut–brain axis influencing microbiome-driven TLR4 signaling. This systematic review aims to describe molecular biomarkers associated with CCM pathophysiology, emphasizing their potential use as diagnostic and prognostic tools. Circulating plasma biomarkers such as CRP, vitamin D, and interleukins may reflect ongoing inflammatory and endothelial processes, while some imaging biomarkers like Quantitative Susceptibility Mapping (QSM) have shown a correlation with iron deposition and vascular leakage. Leveraging both circulating and imaging biomarkers may improve the therapeutic decision-making process. Further studies are encouraged to validate these findings and to facilitate the development of personalized, evidence-based strategies for the management of CCM.
- Open Access
COVID-19 and Influenza Booster Vaccination Elicits Robust Antibody Responses in Patients with Primary Brain Tumors Comparable to Healthy Adults
Background: Patients with primary brain tumors face profound disease- and treatment-related immunosuppression, placing them at high risk for severe infections. Their capacity to mount protective immune responses to vaccination, particularly to repeated antigen exposures such as COVID-19 boosters, remains critically under-defined, leading to uncertainty in clinical practice. Methods: In this prospective cohort study, we analyzed humoral responses to seasonal COVID-19 (mRNA-based) and influenza vaccination in 17 patients with primary brain tumors (recruited from an initial cohort of 37) who received a booster shot, and 19 healthy controls. Serum samples were collected before (T1) and 30 ± 2 days after (T2) vaccination to quantify SARS-CoV-2 anti-Spike (S) IgG and anti-Influenza IgG titers. Results: Despite ongoing chemotherapy in 47% of patients, baseline anti-S antibody titers were comparable between groups. Following the booster, median anti-S titers increased significantly and to a similar magnitude in both patients (from 5030 to 18,500 BAU/mL; IQR: 13,885–24,420) and controls (from 4429 to 20,200 BAU/mL; IQR: 11,075–26,680; p = 0.6137, Mann–Whitney U test). Only two heavily pre-treated patients showed no booster response. All participants showed sero-positivity to Anti-Influenza IgG at baseline. For the primary brain tumor cohort, a significant increase for anti-Influenza IgG at T2 was observed (p = 0.0002). Mean antibody titers did not differ between both cohorts. Conclusions: Our findings provide evidence that patients with primary brain tumors can mount robust recall immunity to mRNA vaccines, addressing clinical uncertainty about booster efficacy in this population. These data provide a strong rationale for prioritizing booster vaccinations in this vulnerable population and argue for the inclusion of these patients in future pivotal vaccine trials.
Open AccessCOVID-19 and Influenza Booster Vaccination Elicits Robust Antibody Responses in Patients with Primary Brain Tumors Comparable to Healthy Adults
Background: Patients with primary brain tumors face profound disease- and treatment-related immunosuppression, placing them at high risk for severe infections. Their capacity to mount protective immune responses to vaccination, particularly to repeated antigen exposures such as COVID-19 boosters, remains critically under-defined, leading to uncertainty in clinical practice. Methods: In this prospective cohort study, we analyzed humoral responses to seasonal COVID-19 (mRNA-based) and influenza vaccination in 17 patients with primary brain tumors (recruited from an initial cohort of 37) who received a booster shot, and 19 healthy controls. Serum samples were collected before (T1) and 30 ± 2 days after (T2) vaccination to quantify SARS-CoV-2 anti-Spike (S) IgG and anti-Influenza IgG titers. Results: Despite ongoing chemotherapy in 47% of patients, baseline anti-S antibody titers were comparable between groups. Following the booster, median anti-S titers increased significantly and to a similar magnitude in both patients (from 5030 to 18,500 BAU/mL; IQR: 13,885–24,420) and controls (from 4429 to 20,200 BAU/mL; IQR: 11,075–26,680; p = 0.6137, Mann–Whitney U test). Only two heavily pre-treated patients showed no booster response. All participants showed sero-positivity to Anti-Influenza IgG at baseline. For the primary brain tumor cohort, a significant increase for anti-Influenza IgG at T2 was observed (p = 0.0002). Mean antibody titers did not differ between both cohorts. Conclusions: Our findings provide evidence that patients with primary brain tumors can mount robust recall immunity to mRNA vaccines, addressing clinical uncertainty about booster efficacy in this population. These data provide a strong rationale for prioritizing booster vaccinations in this vulnerable population and argue for the inclusion of these patients in future pivotal vaccine trials.
- Open Access
- 25 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 168
Calcification of the Internal Carotid Artery and Its Influence on the Severity of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Background/Objectives: Cerebral vasospasm (CV) is a serious complication of aneurysmal subarachnoid hemorrhage (aSAH). Carotid siphon calcification (CSC) has been associated with a reduced risk of CV. This study investigates the influence of CSC on the clinical and radiographic severity of CV and functional outcome of aSAH. Methods: A total of 475 patients with aSAH treated at the University Hospital Essen (2008–2016) were analyzed retrospectively. CSC was assessed using the Woodcock score. Study endpoints were the CV severity in digital subtraction angiography, presence of CV in transcranial Doppler (TCD) ultra-sonography, occurrence of delayed ischemic neurological deficit (DIND) and the functional outcome at 6 months measured with the modified Rankin scale. Results: CSC was confirmed as an independent predictor for the occurrence (aOR 0.76; 95% CI 0.60–0.97; p = 0.025) and severity (RC −0.14; 95% CI −0.24 to −0.04; p = 0.006) of angiographic CV and development of DIND (aOR 0.76; 95% CI 0.59–0.98; p = 0.034). Only the duration (in days: RC −0.43; 95% CI −0.77 to −0.10; p = 0.010) but not the presence (aOR 0.87; 95% CI 0.68 to 1.11; p = 0.265) and severity (cerebral blood flow, in cm/s: RC +1.57; 95% CI −7.45 to +10.58; p = 0.731) of TCD CV was associated with CSC. Finally, the increasing levels of CSC were related to poorer 6-month functional outcome (RC +0.12; 95% CI +0.05 to +0.18; p < 0.001). Conclusions: CSC appears to be protective against angiographic CV and DIND, but correlates with worse overall outcome, suggesting that atherosclerosis, represented by CSC, affects cerebrovascular regulation and overall prognosis. We suggest careful evaluation of primary imaging studies for markers of atherosclerosis to identify patients at risk for CV and patients with low risk for CV but still at high risk for poor outcome.
- 25 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 168
Open AccessCalcification of the Internal Carotid Artery and Its Influence on the Severity of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Background/Objectives: Cerebral vasospasm (CV) is a serious complication of aneurysmal subarachnoid hemorrhage (aSAH). Carotid siphon calcification (CSC) has been associated with a reduced risk of CV. This study investigates the influence of CSC on the clinical and radiographic severity of CV and functional outcome of aSAH. Methods: A total of 475 patients with aSAH treated at the University Hospital Essen (2008–2016) were analyzed retrospectively. CSC was assessed using the Woodcock score. Study endpoints were the CV severity in digital subtraction angiography, presence of CV in transcranial Doppler (TCD) ultra-sonography, occurrence of delayed ischemic neurological deficit (DIND) and the functional outcome at 6 months measured with the modified Rankin scale. Results: CSC was confirmed as an independent predictor for the occurrence (aOR 0.76; 95% CI 0.60–0.97; p = 0.025) and severity (RC −0.14; 95% CI −0.24 to −0.04; p = 0.006) of angiographic CV and development of DIND (aOR 0.76; 95% CI 0.59–0.98; p = 0.034). Only the duration (in days: RC −0.43; 95% CI −0.77 to −0.10; p = 0.010) but not the presence (aOR 0.87; 95% CI 0.68 to 1.11; p = 0.265) and severity (cerebral blood flow, in cm/s: RC +1.57; 95% CI −7.45 to +10.58; p = 0.731) of TCD CV was associated with CSC. Finally, the increasing levels of CSC were related to poorer 6-month functional outcome (RC +0.12; 95% CI +0.05 to +0.18; p < 0.001). Conclusions: CSC appears to be protective against angiographic CV and DIND, but correlates with worse overall outcome, suggesting that atherosclerosis, represented by CSC, affects cerebrovascular regulation and overall prognosis. We suggest careful evaluation of primary imaging studies for markers of atherosclerosis to identify patients at risk for CV and patients with low risk for CV but still at high risk for poor outcome.
- Open Access
- 2 December 2025
- Published by Walter de Gruyter GmbH in Innovative Surgical Sciences
Preoperative HRQoL predicts postoperative olfactory performance in patients undergoing endoscopic transsphenoidal surgery for pituitary adenoma
Objectives: The relation of objective measures of olfactory function and health-related quality of life (HRQoL) in patients with pituitary adenoma after endoscopic transsphenoidal surgery is not well investigated yet. We examined HRQoL of pituitary adenoma patients pre- and postsurgery, in addition to olfactory performance as an objective measure of sinonasal health. Methods: Thirty patients with pituitary adenoma were included in this prospective observational study. They completed the Sniffin’ Sticks test as well as measures of HRQoL before and after bi-nostril endoscopic transsphenoidal surgery. Results: Olfactory performance and HRQoL were correlated in the physical (r s =0.462, p=0.010) but not in the psychological HRQoL domain. While psychological HRQoL tended to ameliorate after surgery (Z=−1.94, p=0.052), physical HRQoL did not. Preoperative physical HRQoL predicted olfactory performance after surgery with an explained variance of 24.9 %, representing a moderate to strong effect; age did not significantly add to the explained variance. Conclusions: In our study, physical HRQoL before surgery of pituitary adenomas as a subjective measure of well-being was highly relevant for objective sinonasal outcome. This finding reinforces the value of preoperative HRQoL assessment as a predictor of postoperative patient health, adding to the benefits of minimally invasive surgical techniques.
- 2 December 2025
- Published by Walter de Gruyter GmbH in Innovative Surgical Sciences
Open AccessPreoperative HRQoL predicts postoperative olfactory performance in patients undergoing endoscopic transsphenoidal surgery for pituitary adenoma
Objectives: The relation of objective measures of olfactory function and health-related quality of life (HRQoL) in patients with pituitary adenoma after endoscopic transsphenoidal surgery is not well investigated yet. We examined HRQoL of pituitary adenoma patients pre- and postsurgery, in addition to olfactory performance as an objective measure of sinonasal health. Methods: Thirty patients with pituitary adenoma were included in this prospective observational study. They completed the Sniffin’ Sticks test as well as measures of HRQoL before and after bi-nostril endoscopic transsphenoidal surgery. Results: Olfactory performance and HRQoL were correlated in the physical (r s =0.462, p=0.010) but not in the psychological HRQoL domain. While psychological HRQoL tended to ameliorate after surgery (Z=−1.94, p=0.052), physical HRQoL did not. Preoperative physical HRQoL predicted olfactory performance after surgery with an explained variance of 24.9 %, representing a moderate to strong effect; age did not significantly add to the explained variance. Conclusions: In our study, physical HRQoL before surgery of pituitary adenomas as a subjective measure of well-being was highly relevant for objective sinonasal outcome. This finding reinforces the value of preoperative HRQoL assessment as a predictor of postoperative patient health, adding to the benefits of minimally invasive surgical techniques.
- Open Access
- 25 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1042
Infarct Timing and Predictors of Infarct-Free Survival in Patients with Aneurysmal Subarachnoid Hemorrhage
Background/Objectives: Cerebral infarction significantly worsens outcomes after aneurysmal subarachnoid hemorrhage (SAH). This retrospective study analyzed early predictors of infarct-free survival and the impact of infarct timing on clinical outcomes. Methods: We reviewed 988 consecutive SAH patients treated from 2003 to 2016, all with follow-up CT scans. Baseline clinical and SAH characteristics were recorded to identify predictors of infarct-free survival and assess the relationship between infarct timing and outcomes. Results: Cerebral infarctions occurred in 475 patients (48.1%) at a median of 3.4 days post-SAH; 70.9% happened within the first week. Earlier infarctions were associated with higher in-hospital mortality (odds ratio [OR] = 0.91 per day increase, p < 0.0001) and poor 6-month outcomes (modified Rankin Scale > 3; OR = 0.96 per day increase, p = 0.012), especially within 48 h. Independent predictors of infarct-free survival included poor initial condition (WFNS ≥ 4, adjusted hazard ratio [aHR] = 1.82, p < 0.0001), intraventricular hemorrhage (aHR = 1.25, p = 0.041), aneurysm rebleeding (aHR = 1.76, p < 0.0001), acute hydrocephalus (aHR = 1.38, p = 0.020), and daily aspirin intake (aHR = 0.68, p = 0.002). The number of baseline risk factors (0–5) strongly influenced both infarction likelihood and timing (p < 0.0001). Conclusions: Cerebral infarctions predominantly occur within the first week after SAH, with earlier infarctions having a more severe impact on outcomes. Initial risk factor-adapted SAH management may improve functional outcomes.
- 25 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1042
Open AccessInfarct Timing and Predictors of Infarct-Free Survival in Patients with Aneurysmal Subarachnoid Hemorrhage
Background/Objectives: Cerebral infarction significantly worsens outcomes after aneurysmal subarachnoid hemorrhage (SAH). This retrospective study analyzed early predictors of infarct-free survival and the impact of infarct timing on clinical outcomes. Methods: We reviewed 988 consecutive SAH patients treated from 2003 to 2016, all with follow-up CT scans. Baseline clinical and SAH characteristics were recorded to identify predictors of infarct-free survival and assess the relationship between infarct timing and outcomes. Results: Cerebral infarctions occurred in 475 patients (48.1%) at a median of 3.4 days post-SAH; 70.9% happened within the first week. Earlier infarctions were associated with higher in-hospital mortality (odds ratio [OR] = 0.91 per day increase, p < 0.0001) and poor 6-month outcomes (modified Rankin Scale > 3; OR = 0.96 per day increase, p = 0.012), especially within 48 h. Independent predictors of infarct-free survival included poor initial condition (WFNS ≥ 4, adjusted hazard ratio [aHR] = 1.82, p < 0.0001), intraventricular hemorrhage (aHR = 1.25, p = 0.041), aneurysm rebleeding (aHR = 1.76, p < 0.0001), acute hydrocephalus (aHR = 1.38, p = 0.020), and daily aspirin intake (aHR = 0.68, p = 0.002). The number of baseline risk factors (0–5) strongly influenced both infarction likelihood and timing (p < 0.0001). Conclusions: Cerebral infarctions predominantly occur within the first week after SAH, with earlier infarctions having a more severe impact on outcomes. Initial risk factor-adapted SAH management may improve functional outcomes.
- Open Access
- 2 July 2025
- Published by Elsevier in World Neurosurgery
- Vol. 200, 124219
Cerebral Cavernous Malformation: The Impact of Associated Developmental Venous Anomaly on Surgical Treatment Outcome
- 2 July 2025
- Published by Elsevier in World Neurosurgery
- Vol. 200, 124219
Open AccessCerebral Cavernous Malformation: The Impact of Associated Developmental Venous Anomaly on Surgical Treatment Outcome
- Open Access
Treatment of Central Neurocytoma
Objective: Central neurocytomas (CNs), classified as CNS (central nervous system) grade 2 tumors, are exceptionally rare tumors, accounting for approximately 0.1–0.5% of all intracranial neoplasms, and are typically characterized by a benign clinical course and frequent association with hydrocephalus. This study aims to present a comprehensive analysis of surgical and adjuvant therapies for CN. Methods: The study comprised all patients who underwent microsurgical tumor removal in our center over the past decade (2013–2023). Clinical manifestations, surgical and adjuvant therapy approaches, MRI and histological findings, clinical outcomes, and recurrence-free survival were evaluated. Results: A total of eleven patients (six men, mean age of 28.0 years; five women, mean age of 53.6 years) underwent surgical treatment. Intraventricular tumors were the most common (72.7%, n = 8). The predominant presenting symptoms were headache and visual disturbances. All tumors exhibited contrast enhancement on MRI. Hydrocephalus was present in five patients. The Ki67 proliferation index ranged from 2% to 10%, with nine patients exhibiting Ki67 > 3%. The median recurrence-free survival was 38.0 months (IQR: 25.0–53.0). The most severe postoperative complications included aphasia, hemiparesis, and memory impairment, resulting in a postoperative Karnofsky Performance Status (KPS) below 70% in five patients. Follow-up assessments showed significant symptomatic improvement in all affected patients. Conclusions: Gross total resection is the recommended first-line therapy with favorable neurological outcomes and for atypical CN as well. Adjuvant radiotherapy should be reserved for tumor progression and recurrence. The role of adjuvant chemotherapy remains unclear, but it may be an option for CN with a high proliferation index.
Open AccessTreatment of Central Neurocytoma
Objective: Central neurocytomas (CNs), classified as CNS (central nervous system) grade 2 tumors, are exceptionally rare tumors, accounting for approximately 0.1–0.5% of all intracranial neoplasms, and are typically characterized by a benign clinical course and frequent association with hydrocephalus. This study aims to present a comprehensive analysis of surgical and adjuvant therapies for CN. Methods: The study comprised all patients who underwent microsurgical tumor removal in our center over the past decade (2013–2023). Clinical manifestations, surgical and adjuvant therapy approaches, MRI and histological findings, clinical outcomes, and recurrence-free survival were evaluated. Results: A total of eleven patients (six men, mean age of 28.0 years; five women, mean age of 53.6 years) underwent surgical treatment. Intraventricular tumors were the most common (72.7%, n = 8). The predominant presenting symptoms were headache and visual disturbances. All tumors exhibited contrast enhancement on MRI. Hydrocephalus was present in five patients. The Ki67 proliferation index ranged from 2% to 10%, with nine patients exhibiting Ki67 > 3%. The median recurrence-free survival was 38.0 months (IQR: 25.0–53.0). The most severe postoperative complications included aphasia, hemiparesis, and memory impairment, resulting in a postoperative Karnofsky Performance Status (KPS) below 70% in five patients. Follow-up assessments showed significant symptomatic improvement in all affected patients. Conclusions: Gross total resection is the recommended first-line therapy with favorable neurological outcomes and for atypical CN as well. Adjuvant radiotherapy should be reserved for tumor progression and recurrence. The role of adjuvant chemotherapy remains unclear, but it may be an option for CN with a high proliferation index.
- Open Access
- 1 May 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 254, 108924
Impact of lifetime and current smoking exposure on the rupture status, number, and size of intracranial aneurysms
- 1 May 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 254, 108924
Open AccessImpact of lifetime and current smoking exposure on the rupture status, number, and size of intracranial aneurysms
- Open Access
- 4 March 2025
- Published by Elsevier in World Neurosurgery
- Vol. 196, 123749
The Course and Clinical Relevance of Interleukin-6 in Cerebrospinal Fluid in Patients with Aneurysmal Subarachnoid Hemorrhage
- 4 March 2025
- Published by Elsevier in World Neurosurgery
- Vol. 196, 123749
Open AccessThe Course and Clinical Relevance of Interleukin-6 in Cerebrospinal Fluid in Patients with Aneurysmal Subarachnoid Hemorrhage